Reviewing Mangoceuticals (MGRX) and Its Competitors

Mangoceuticals (NASDAQ:MGRX) is one of 233 public companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its competitors? We will compare Mangoceuticals to related companies based on the strength of its earnings, valuation, analyst recommendations, institutional ownership, profitability, risk and dividends.

Volatility & Risk

Mangoceuticals has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, Mangoceuticals’ competitors have a beta of 0.96, suggesting that their average stock price is 4% less volatile than the S&P 500.

Insider and Institutional Ownership

56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 56.8% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by company insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for Mangoceuticals and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1	0	0	0	1.00
Mangoceuticals Competitors	1841	7697	13236	815	2.55

As a group, “Healthcare Providers & Services” companies have a potential upside of 14.95%. Given Mangoceuticals’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Mangoceuticals has less favorable growth aspects than its competitors.

Profitability

This table compares Mangoceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
Mangoceuticals Competitors	-7.78%	-141.21%	-1.54%

Valuation and Earnings

This table compares Mangoceuticals and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mangoceuticals	$460,000.00	-$20.64 million	-0.23
Mangoceuticals Competitors	$21.01 billion	$288.48 million	7.18

Mangoceuticals’ competitors have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Mangoceuticals competitors beat Mangoceuticals on 10 of the 13 factors compared.

Mangoceuticals Company Profile

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.